Relief Therapeutics Holding AG (RLFTF)

[kizmyarse]

Am I late a seeing this PR ?


NeuroRx
HomeNews
News

Press ReleasesSeptember 23, 2020
NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy
CISON PR Newswire Emergency Use Authorization request targets the same population as is currently permitted under FDA Expanded Access Protocol RADNOR, Pa., Sept. 23, 2020 /PRNewswire/ — NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100™ aviptadil in patients who are receiving intensive care […]

Read more

NewsAugust 5, 2020
Which COVID-19 treatments are showing promise? A list of potential drugs
By Lia Eustachewich, NY Post The race is on to find a treatment that works to quash the coronavirus — as the deadly disease continues to spread across the globe. Here’s a list of the most promising treatments and potential vaccines for SARS-CoV-2, the virus that causes COVID-19. Remdesivir The experimental antiviral drug, made by Gilead Sciences, was […]

Read more

BroadcastsJune 15, 2020
Prof Jonathan Javitt joins i24NEWS – FDA Grants Continuation of COVID-19 Trial

Read more

Press ReleasesSeptember 21, 2020
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners
CISON PR Newswire GENEVA, Switzerland and RADNOR, Pa., Sept. 21, 2020 /PRNewswire/ — RELIEF THERAPEUTICS Holding SA (SIX: RLF,OTCQB: RLFTF) (“Relief” or the “Company“) and NeuroRx, Inc. today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil) worldwide. The two organizations have agreed to share all profits from sales of RLF-100 for […]